272 related articles for article (PubMed ID: 36992496)
1. Opportunities for CAR-T Cell Immunotherapy in HIV Cure.
Campos-Gonzalez G; Martinez-Picado J; Velasco-Hernandez T; Salgado M
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992496
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
3. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
4. Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure.
Li S; Wang H; Guo N; Su B; Lambotte O; Zhang T
Chin Med J (Engl); 2023 Nov; 136(22):2658-2667. PubMed ID: 37927030
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell approaches to HIV cure.
Kuhlmann AS; Peterson CW; Kiem HP
Curr Opin HIV AIDS; 2018 Sep; 13(5):446-453. PubMed ID: 29878913
[TBL] [Abstract][Full Text] [Related]
6. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.
Liu B; Zhang W; Zhang H
Curr Opin Virol; 2019 Oct; 38():21-30. PubMed ID: 31132749
[TBL] [Abstract][Full Text] [Related]
7. Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.
Mao Y; Zhao C; Zheng P; Zhang X; Xu J
Immunotherapy; 2021 Feb; 13(2):177-184. PubMed ID: 33225803
[TBL] [Abstract][Full Text] [Related]
8. Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment.
Adabi N; Pordel S; Rezaee MA; Shobeiri FS; Shobeiri SS
J Gene Med; 2023 May; 25(5):e3484. PubMed ID: 36781390
[TBL] [Abstract][Full Text] [Related]
9. Advances in Developing CAR T-Cell Therapy for HIV Cure.
Qi J; Ding C; Jiang X; Gao Y
Front Immunol; 2020; 11():361. PubMed ID: 32210965
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV.
Iwamoto N; Patel B; Song K; Mason R; Bolivar-Wagers S; Bergamaschi C; Pavlakis GN; Berger E; Roederer M
PLoS One; 2021; 16(3):e0248973. PubMed ID: 33752225
[TBL] [Abstract][Full Text] [Related]
11. Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies.
Buck AM; Deveau TM; Henrich TJ; Deitchman AN
Viruses; 2023 May; 15(5):. PubMed ID: 37243212
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
13. False-Positive Results for Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy.
Hauser JR; Hong H; Babady NE; Papanicolaou GA; Tang YW
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31694968
[TBL] [Abstract][Full Text] [Related]
14. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
[TBL] [Abstract][Full Text] [Related]
15. Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir
York J; Gowrishankar K; Micklethwaite K; Palmer S; Cunningham AL; Nasr N
Front Immunol; 2022; 13():873701. PubMed ID: 35572509
[TBL] [Abstract][Full Text] [Related]
16. Quarter Century of Anti-HIV CAR T Cells.
Wagner TA
Curr HIV/AIDS Rep; 2018 Apr; 15(2):147-154. PubMed ID: 29500712
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.
Liu B; Zhang W; Xia B; Jing S; Du Y; Zou F; Li R; Lu L; Chen S; Li Y; Hu Q; Lin Y; Zhang Y; He Z; Zhang X; Chen X; Peng T; Tang X; Cai W; Pan T; Li L; Zhang H
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375315
[TBL] [Abstract][Full Text] [Related]
19. Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.
Haran KP; Hajduczki A; Pampusch MS; Mwakalundwa G; Vargas-Inchaustegui DA; Rakasz EG; Connick E; Berger EA; Skinner PJ
Front Immunol; 2018; 9():492. PubMed ID: 29616024
[TBL] [Abstract][Full Text] [Related]
20. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
